Biotoxtech

At a glance

Biotoxtech filed 47 disclosures in the last 12 months, including 15 insider and 15 5% holder. The most recent key filing was on Oct 26: CEO bought 980 sh on the market at an average ₩2,029, Oct 22.

Revenue for 2025 was ₩47B, up 13.7% on 2024. It made an operating loss of ₩4.8B. Debt was 312% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩26.3B and operating loss of ₩2B.

The 2025 annual report lists 241 employees with an average tenure of 3.5 years and average pay of ₩47M, #1585 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩217M each on average. It paid no cash dividend for 2025. 강종구 and related parties held 23.11% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 24.31% on Oct 26.

From the 2025 annual report

Staff: 241 (110 men, 131 women), of whom 76 on fixed-term contracts. Total pay for the year: ₩11.4B. Directors and auditors: 4, paid ₩867M in total.

No cash dividend was paid for 2025.

Largest shareholder

강종구 holds 12.76%; with 9 related parties the group holds 23.11% of common shares at year end (from 22.70% at the start of the year).

Auditor: 동성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports